Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress

Free Radical Biology and Medicine

Volumn 51, Issue 5, 2011, Pages 1054-1061

  Booz, George W ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Endocannabinoid; Free radicals; Immune system; Inflammation; Metabolic syndrome; Oxidative stress

Indexed keywords

ADENOSINE RECEPTOR; CANNABIDIOL; CASPASE 8; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALZHEIMER DISEASE; APOPTOSIS; ATHEROSCLEROSIS; BIOCHEMISTRY; CARDIOVASCULAR RISK; DEPRESSION; DISEASE COURSE; DRUG STRUCTURE; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; IC 50; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; METABOLIC SYNDROME X; NATURAL KILLER CELL; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CANNABIDIOL; DIABETES MELLITUS; ENDOCANNABINOIDS; HUMANS; IMMUNITY; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEURALGIA; OXIDATIVE STRESS; REPERFUSION INJURY;

EID: 80051664599     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2011.01.007     Document Type: Review

References (101)

1. A.A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, and R. Mechoulam Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Trends Pharmacol. Sci. 30 2009 515 527
2. R. Mechoulam, M. Peters, E. Murillo-Rodriguez, and L.O. Hanus Cannabidiol-recent advances Chem. Biodivers. 4 2007 1678 1692
3. A.W. Zuardi Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action Rev. Bras. Psiquiatr. 30 2008 271 280
4. 2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels J. Neuroimmune Pharmacol. 5 2010 103 121
5. E.S. Graham, J.C. Ashton, and M. Glass Cannabinoid receptors: a brief history and "what's hot" Front. Biosci. 14 2009 944 957
6. R. Tanasescu, and C.S. Constantinescu Cannabinoids and the immune system: an overview Immunobiology 215 2010 588 597
7. P. Pacher, and S. Steffens The emerging role of the endocannabinoid system in cardiovascular disease Semin. Immunopathol. 31 2009 63 77
8. S. Bátkai, and P. Pacher Endocannabinoids and cardiac contractile function: pathophysiological implications Pharmacol. Res. 60 2009 99 106
9. A.J. Hampson, M. Grimaldi, M. Lolic, D. Wink, R. Rosenthal, and J. Axelrod Neuroprotective antioxidants from marijuana Ann. NY Acad. Sci. 899 2000 274 282 (Pubitemid 30352793)
10. Y. Chen, and J. Buck Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism J. Pharmacol. Exp. Ther. 293 2000 807 812 (Pubitemid 30417845)
11. C. Hamelink, A. Hampson, D.A. Wink, L.E. Eiden, and R.L. Eskay Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity J. Pharmacol. Exp. Ther. 314 2005 780 788 (Pubitemid 41043862)
12. M. García-Arencibia, S. González, E. de Lago, J.A. Ramos, R. Mechoulam, and J. Fernández-Ruiz Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties Brain Res. 1134 2007 162 170 (Pubitemid 46135535)
13. 9-tetrahydrocannabivarin Br. J. Pharmacol. 153 2008 199 215
14. R. Capasso, F. Borrelli, G. Aviello, B. Romano, C. Scalisi, F. Capasso, and A.A. Izzo Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice Br. J. Pharmacol. 154 2008 1001 1008 (Pubitemid 351915071)
15. 2A adenosine receptor Investig. Ophthalmol. Vis. Sci. 49 2008 5526 5531
16. E.J. Carrier, J.A. Auchampach, and C.J. Hillard Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression Proc. Natl Acad. Sci. USA 103 2006 7895 7900
17. 2B adenosine receptors in immunity and inflammation Trends Immunol. 30 2009 263 270
18. G. Haskó, J. Linden, B. Cronstein, and P. Pacher Adenosine receptors: therapeutic aspects for inflammatory and immune diseases Nat. Rev. Drug Discovery 7 2008 759 770
19. M. Rajesh, P. Mukhopadhyay, S. Bátkai, G. Haskó, L. Liaudet, V.R. Drel, I.G. Obrosova, and P. Pacher Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption Am. J. Physiol. Heart Circ. Physiol. 293 2007 H610 H619
20. H. Pan, P. Mukhopadhyay, M. Rajesh, V. Patel, B. Mukhopadhyay, B. Gao, G. Haskó, and P. Pacher Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death J. Pharmacol. Exp. Ther. 328 2009 708 714
21. 9-Tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro J. Neuroimmunol. 207 2009 75 82
22. 2 Mol. Pharmacol. 73 2008 441 450 (Pubitemid 351159214)
23. L. Walter, A. Franklin, A. Witting, C. Wade, Y. Xie, G. Kunos, K. Mackie, and N. Stella Nonpsychotropic cannabinoid receptors regulate microglial cell migration J. Neurosci. 23 2003 1398 1405 (Pubitemid 36258918)
24. D. McHugh, S.S. Hu, N. Rimmerman, A. Juknat, Z. Vogel, J.M. Walker, and H.B. Bradshaw N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor BMC Neurosci. 26 2010 44
25. A.B. El-Remessy, Y. Tang, G. Zhu, S. Matragoon, Y. Khalifa, E.K. Liu, J.Y. Liu, E. Hanson, S. Mian, N. Fatteh, and G.I. Liou Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation Mol. Vis. 14 2008 2190 2203
26. 9-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-κB and interferon-β/STAT proinflammatory pathways in BV-2 microglial cells J. Biol. Chem. 285 2010 1616 1626
27. H.Y. Wu, A.C. Chang, C.C. Wang, F.H. Kuo, C.Y. Lee, D.Z. Liu, and T.R. Jan Cannabidiol induced a contrasting pro-apoptotic effect between freshly isolated and precultured human monocytes Toxicol. Appl. Pharmacol. 246 2011 141 147
28. H.Y. Wu, R.M. Chu, C.C. Wang, C.Y. Lee, S.H. Lin, and T.R. Jan Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8 Toxicol. Appl. Pharmacol. 226 2008 260 270
29. C.Y. Lee, S.P. Wey, M.H. Liao, W.L. Hsu, H.Y. Wu, and T.R. Jan A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells Int. Immunopharmacol. 8 2008 732 740
30. H.Y. Wu, and T.R. Jan Cannabidiol hydroxyquinone-induced apoptosis of splenocytes is mediated predominantly by thiol depletion Toxicol. Lett. 195 2010 68 74
31. phox and Nox4 expression Mol. Pharmacol. 70 2006 897 908 (Pubitemid 44268447)
32. B. Ignatowska-Jankowska, M. Jankowski, W. Glac, and A.H. Swiergel Cannabidiol-induced lymphopenia does not involve NKT and NK cells J. Physiol. Pharmacol. 60 Suppl. 3 2009 99 103
33. R. Baron, A. Binder, and G. Wasner Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment Lancet Neurol. 9 2010 807 819
34. D. Kim, B. You, E.K. Jo, S.K. Han, M.I. Simon, and S.J. Lee NADPH oxidase 2-derived reactive oxygen species in spinal cord microglia contribute to peripheral nerve injury-induced neuropathic pain Proc. Natl Acad. Sci. USA 107 2010 14851 14856
35. E.J. Rahn, and A.G. Hohmann Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside Neurotherapeutics 6 2009 713 737
36. C.C. Toth, N.M. Jedrzejewski, C.L. Ellis, and W.H. Frey 2nd. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain Mol. Pain 6 2010 16
37. D.R. Blake, P. Robson, M. Ho, R.W. Jubb, and C.S. McCabe Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis Rheumatology (Oxford) 45 2006 50 52 (Pubitemid 43033874)
38. A.M. Malfait, R. Gallily, P.F. Sumariwalla, A.S. Malik, E. Andreakos, R. Mechoulam, and M. Feldmann The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis Proc. Natl Acad. Sci. USA 97 2000 9561 9566 (Pubitemid 30650815)
39. L. Weiss, M. Zeira, S. Reich, M. Har-Noy, R. Mechoulam, S. Slavin, and R. Gallily Cannabidiol lowers incidence of diabetes in non-obese diabetic mice Autoimmunity 39 2006 143 151 (Pubitemid 43675258)
40. L. Weiss, M. Zeira, S. Reich, S. Slavin, I. Raz, R. Mechoulam, and R. Gallily Cannabidiol arrests onset of autoimmune diabetes in NOD mice Neuropharmacology 54 2008 244 249 (Pubitemid 350299408)
41. P. Pacher, J.S. Beckman, and L. Liaudet Nitric oxide and peroxynitrite in health and disease Physiol. Rev. 87 2007 315 342
42. A.B. El-Remessy, M. Al-Shabrawey, Y. Khalifa, N.T. Tsai, R.B. Caldwell, and G.I. Liou Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes Am. J. Pathol. 168 2006 235 244 (Pubitemid 43062576)
43. K. Noda, S. Nakao, S. Zandi, V. Engelstädter, Y. Mashima, and A. Hafezi-Moghadam Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes Exp. Eye Res. 89 2009 774 781
44. A.B. El-Remessy, Y. Khalifa, S. Ola, A.S. Ibrahim, and G.I. Liou Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes Mol. Vis. 16 2010 1487 1495
45. M. Rajesh, P. Mukhopadhyay, S. Bátkai, V. Patel, K. Saito, S. Matsumoto, Y. Kashiwaya, B. Horváth, B. Mukhopadhyay, L. Becker, G. Haskó, L. Liaudet, D.A. Wink, A. Veves, R. Mechoulam, and P. Pacher Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy J. Am. Coll. Cardiol. 56 2010 2115 2125
46. P. Shi, C. Diez-Freire, J.Y. Jun, Y. Qi, M.J. Katovich, Q. Li, S. Sriramula, J. Francis, C. Sumners, and M.K. Raizada Brain microglial cytokines in neurogenic hypertension Hypertension 56 2010 297 303
47. D.G. Harrison, A. Vinh, H. Lob, and M.S. Madhur Role of the adaptive immune system in hypertension Curr. Opin. Pharmacol. 10 2010 203 207
48. C. De Miguel, S. Das, H. Lund, and D.L. Mattson T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats Am. J. Physiol. Regul. Integr. Comp. Physiol. 298 2010 R1136 R1142
49. Y. Azekoshi, T. Yasu, S. Watanabe, T. Tagawa, S. Abe, K. Yamakawa, Y. Uehara, S. Momomura, H. Urata, and S. Ueda Free fatty acid causes leukocyte activation and resultant endothelial dysfunction through enhanced angiotensin II production in mononuclear and polymorphonuclear cells Hypertension 56 2010 136 142
50. P.J. Marvar, S.R. Thabet, T.J. Guzik, H.E. Lob, L.A. McCann, C. Weyand, F.J. Gordon, and D.G. Harrison Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension Circ. Res. 107 2010 263 270
51. W. Chao Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart Am. J. Physiol. Heart Circ. Physiol. 296 2009 H1 H12
52. R. Durst, H. Danenberg, R. Gallily, R. Mechoulam, K. Meir, E. Grad, R. Beeri, T. Pugatsch, E. Tarsish, and C. Lotan Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury Am. J. Physiol. Heart Circ. Physiol. 293 2007 H3602 H3607
53. M.H. Napimoga, B.B. Benatti, F.O. Lima, P.M. Alves, A.C. Campos, D.R. Pena-Dos-Santos, F.P. Severino, F.Q. Cunha, and F.S. Guimarães Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats Int. Immunopharmacol. 9 2009 216 222
54. A.M. Johnstone, A. Koh, M.B. Goldberg, and M. Glogauer A hyperactive neutrophil phenotype in patients with refractory periodontitis J. Periodontol. 78 2007 1788 1794
55. K. Hayakawa, K. Mishima, M. Nozako, M. Hazekawa, K. Irie, M. Fujioka, K. Orito, K. Abe, N. Hasebe, N. Egashira, K. Iwasaki, and M. Fujiwara Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism J. Neurochem. 102 2007 1488 1496 (Pubitemid 47256190)
56. K. Hayakawa, K. Irie, K. Sano, T. Watanabe, S. Higuchi, M. Enoki, T. Nakano, K. Harada, S. Ishikane, T. Ikeda, M. Fujioka, K. Orito, K. Iwasaki, K. Mishima, and M. Fujiwara Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box 1-inhibiting mechanism Biol. Pharm. Bull. 32 2009 1538 1544
57. 9- tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L Pharmacol. Biochem. Behav. 95 2010 434 442
58. 1A receptors Br. J. Pharmacol. 159 2010 122 128
59. M. Maes, P. Galecki, Y.S. Chang, and M. Berk A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 676 692
60. C. Song, and H. Wang Cytokines mediated inflammation and decreased neurogenesis in animal models of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 760 768
61. T. Heurtaux, A. Michelucci, S. Losciuto, C. Gallotti, P. Felten, G. Dorban, L. Grandbarbe, E. Morga, and P. Heuschling Microglial activation depends on beta-amyloid conformation: role of the formylpeptide receptor 2 J. Neurochem. 114 2010 576 586
62. M.T. Heneka, J.J. Rodríguez, and A. Verkhratsky Neuroglia in neurodegeneration Brain Res. Rev. 63 2010 189 211
63. G. Candore, M. Bulati, C. Caruso, L. Castiglia, G. Colonna-Romano, D. Di Bona, G. Duro, D. Lio, D. Matranga, M. Pellicanò, C. Rizzo, G. Scapagnini, and S. Vasto Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications Rejuvenation Res. 13 2010 301 313
64. E. Tamagno, P. Bardini, M. Guglielmotto, O. Danni, and M. Tabaton The various aggregation states of β-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression Free Radic. Biol. Med. 41 2006 202 212 (Pubitemid 43928492)
65. M. Sastre, T. Klockgether, and M.T. Heneka Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms Int. J. Dev. Neurosci. 24 2006 167 176 (Pubitemid 43294623)
66. C.Y. Lee, and G.E. Landreth The role of microglia in amyloid clearance from the AD brain J. Neural Transm. 117 2010 949 960
67. Njie, E. G.; Boelen, E.; Stassen, F. R.; Steinbusch, H. W.; Borchelt, D. R.; Streit, W.J. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol. Aging (in press).
68. T. Malm, M. Koistinaho, A. Muona, J. Magga, and J. Koistinaho The role and therapeutic potential of monocytic cells in Alzheimer's disease Glia 58 2010 889 900
69. T. Bisogno, and V. Di Marzo The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses Curr. Pharm. Des. 14 2008 2299 3305
70. A.W. Zuardi, J.A. Crippa, J.E. Hallak, J.P. Pinto, M.H. Chagas, G.G. Rodrigues, S.M. Dursun, and V. Tumas Cannabidiol for the treatment of psychosis in Parkinson's disease J. Psychopharmacol. 23 2009 979 983
71. T. Iuvone, G. Esposito, D. De Filippis, C. Scuderi, and L. Steardo Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci. Ther. 15 2009 65 75
72. T. Iuvone, G. Esposito, R. Esposito, R. Santamaria, M. Di Rosa, and A.A. Izzo Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells J. Neurochem. 89 2004 134 141 (Pubitemid 38420682)
73. G. Esposito, D. De Filippis, M.C. Maiuri, D. De Stefano, R. Carnuccio, and T. Iuvone Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-κB involvement Neurosci. Lett. 399 2006 91 95
74. G. Esposito, C. Scuderi, C. Savani, L. Steardo Jr., D. De Filippis, P. Cottone, T. Iuvone, V. Cuomo, and L. Steardo Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression Br. J. Pharmacol. 151 2007 1272 1279 (Pubitemid 47255904)
75. S.S. Valvassori, G. Elias, B. de Souza, F. Petronilho, F. Dal-Pizzol, F. Kapczinski, C. Trzesniak, V. Tumas, S. Dursun, M.H. Chagas, J.E. Hallak, A.W. Zuardi, J. Quevedo, and J.A. Crippa Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania J. Psychopharmacol. 25 2011 274 280
76. R. Monteiro, and I. Azevedo Chronic inflammation in obesity and the metabolic syndrome Mediat. Inflamm. 2010 2010 289645
77. K.P. Karalis, P. Giannogonas, E. Kodela, Y. Koutmani, M. Zoumakis, and T. Teli Mechanisms of obesity and related pathology: linking immune responses to metabolic stress FEBS J. 276 2009 5747 5754
78. N. Houstis, E.D. Rosen, and E.S. Lander Reactive oxygen species have a causal role in multiple forms of insulin resistance Nature 440 2006 944 948
79. D. Samocha-Bonet, L.K. Heilbronn, D. Lichtenberg, and L.V. Campbell Does skeletal muscle oxidative stress initiate insulin resistance in genetically predisposed individuals? Trends Endocrinol. Metab. 21 2010 83 88
80. T. Suganami, and Y. Ogawa Adipose tissue macrophages: their role in adipose tissue remodeling J. Leukoc. Biol. 88 2010 33 39
81. L. Fuentes, T. Roszer, and M. Ricote Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages Mediat. Inflamm. 2010 2010 219583
82. A. Chawla Control of macrophage activation and function by PPARs Circ. Res. 106 2010 1559 1569
83. S.E. O'Sullivan, and D.A. Kendall Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease Immunobiology 215 2010 611 616
84. S.E. O'Sullivan, Y. Sun, A.J. Bennett, M.D. Randall, and D.A. Kendall Time-dependent vascular actions of cannabidiol in the rat aorta Eur. J. Pharmacol. 612 2009 61 68
85. F.J. Bermudez-Silva, M.P. Viveros, J.M. McPartland, and F. Rodriguez de Fonseca The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol. Biochem. Behav. 95 2010 375 382
86. S. Kaul, A.F. Bolger, D. Herrington, R.P. Giugliano, and R.H. Eckel Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation Circulation 121 2010 1868 1877
87. D.M. Riche, and S. Travis King Bone loss and fracture risk associated with thiazolidinedione therapy Pharmacotherapy 30 2010 716 727
88. P. Saha, B. Modarai, J. Humphries, K. Mattock, M. Waltham, K.G. Burnand, and A. Smith The monocyte/macrophage as a therapeutic target in atherosclerosis Curr. Opin. Pharmacol. 9 2009 109 118
89. M. Hulsmans, and P. Holvoet The vicious circle between oxidative stress and inflammation in atherosclerosis J. Cell. Mol. Med. 14 2010 70 78
90. S. Takeda, N. Usami, I. Yamamoto, and K. Watanabe Cannabidiol-2′, 6′-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor Drug Metab. Dispos. 37 2009 1733 1737
91. M. Hersberger Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins Clin. Chem. Lab. Med. 48 2010 1063 1073
92. S. Immenschuh Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work? Cardiovasc. Res. 84 2009 341 342
93. K.H. Han, S. Lim, J. Ryu, C.W. Lee, Y. Kim, J.H. Kang, S.S. Kang, Y.K. Ahn, C.S. Park, and J.J. Kim CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages Cardiovasc. Res. 84 2009 378 386
94. L.S. Jiang, J. Pu, Z.H. Han, L.H. Hu, and B. He Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages Cardiovasc. Res. 81 2009 805 813
95. M.X. Hao, L.S. Jiang, N.Y. Fang, J. Pu, L.H. Hu, L.H. Shen, W. Song, and B. He The cannabinoid WIN55, 212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages J. Lipid Res. 51 2010 2181 2190
96. 2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion Am. J. Physiol. Heart Circ. Physiol. 293 2007 H2210 H2218
97. M. Rajesh, P. Mukhopadhyay, G. Haskó, L. Liaudet, K. Mackie, and P. Pacher Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells Br. J. Pharmacol. 160 2010 688 700
98. 1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes Cardiovasc. Res. 85 2010 773 784
99. 2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion J. Mol. Cell. Cardiol. 46 2009 612 620
100. P. Mukhopadhyay, M. Rajesh, H. Pan, V. Patel, B. Mukhopadhyay, S. Bátkai, B. Gao, G. Haskó, and P. Pacher Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy Free Radic. Biol. Med. 48 2010 457 467
101. 1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model Br. J. Pharmacol. 160 2010 657 668